Log In
BCIQ
Print this Print this
 

Qtern, saxagliptin/dapagliflozin

Also known as: dapagliflozin/saxagliptin

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionCombination of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and saxagliptin, a dipeptidyl peptidase-4 (DPP-4; CD26) inhibitor
Molecular Target Sodium-glucose cotransporter 2 (SGLT2) ; Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of ActionSodium-glucose cotransporter 2 (SGLT2) inhibitor; Dipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentApproved
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
PartnerAstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today